INTRAVITREAL INJECTION OF RANIBIZUMAB DURING CATARACT SURGERY IN PATIENTS WITH DIABETIC MACULAR EDEMA
| Autor: | Rodrigo Jorge, Felipe Almeida, Andre Messias, Ingrid U. Scott, Paulo I. Rauen, Jefferson Augusto Santana Ribeiro |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Intraocular pressure Visual acuity genetic structures medicine.medical_treatment Visual Acuity Angiogenesis Inhibitors Antibodies Monoclonal Humanized Cataract Macular Edema Retina ESTUDOS PROSPECTIVOS Lens Implantation Intraocular Ranibizumab Ophthalmology medicine Humans Prospective Studies Fluorescein Angiography Prospective cohort study Intraocular Pressure Aged Diabetic Retinopathy Phacoemulsification medicine.diagnostic_test business.industry General Medicine Diabetic retinopathy Cataract surgery medicine.disease Fluorescein angiography eye diseases Intravitreal Injections Female sense organs medicine.symptom business Tomography Optical Coherence medicine.drug |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 0275-004X |
| DOI: | 10.1097/iae.0b013e31824bebb8 |
| Popis: | PURPOSE To investigate macular thickness and visual acuity changes after 1 intravitreal injection of 0.5-mg ranibizumab during phacoemulsification cataract surgery in eyes with diabetic macular edema refractory to laser treatment. METHODS Eleven eyes of 11 patients with diabetic macular edema refractory to modified Early Treatment Diabetic Retinopathy Study laser therapy received intravitreal during phacoemulsification cataract surgery. Comprehensive ophthalmic evaluation was performed preoperatively and at 1, 4, 8 ± 1, and 12 ± 2 weeks postoperatively. Main outcome measures included central subfield thickness and best-corrected Early Treatment Diabetic Retinopathy Study visual acuity. RESULTS Eleven patients completed the 12-week study visit. Mean central subfield thickness (± SEM) was 399.82 ± 29.50 μm at baseline and did not change significantly at any postoperative study visit (P > 0.05). Mean (± SEM) best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was 0.95 ± 0.13 logarithm of the minimum angle of resolution (20/200) at baseline and was significantly improved at Weeks 1 (0.38 ± 0.13), 4 (0.38 ± 0.11), 8 (0.35 ± 0.08), and 12 (0.46 ± 0.12) after treatment (P < 0.05). CONCLUSION In this case series of patients with diabetic macular edema refractory to laser therapy, intravitreal ranibizumab administered during cataract surgery was associated with no significant change in central subfield thickness postoperatively. Significant improvement in best-corrected Early Treatment Diabetic Retinopathy Study visual acuity was observed after treatment, likely because of cataract removal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|